Beacon Therapeutics reported that its X-linked retinitis pigmentosa gene therapy, laruparetigene zovaparvovec (laru-zova), met the primary endpoint in the FDA-endorsed pivotal VISTA study. The company said responders—defined by low-luminance visual acuity (LLVA) gains—were seen in both dose cohorts, while the untreated control group showed no such response. The win positions Beacon closer to a BLA submission as it prepares for regulatory review. Investors will also be looking at durability signals and how the dataset compares with gene therapy benchmarks in inherited retinal disease.